Search
CTT-1057
go.drugbank.com/drugs/DB14965InvestigationalCTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).
AEM-28
go.drugbank.com/drugs/DB17642InvestigationalAEM-28 is a 28 amino acid mimetic of apolipoprotein E being investigated for lipid disorders, such as homozygous familial hypercholesterolemia. It possesses anti-inflammatory properties.[A258764]
Abetimus
go.drugbank.com/drugs/DB06662InvestigationalAbetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
Allosamidin
go.drugbank.com/drugs/DB04628ExperimentalAllosamidin exhibits extremely potent inhibitory activity against chitinases from a number of sources, particularly from <i>Candida albicans</i>, and can be utilized as potent antifungal agent.
Votucalis
go.drugbank.com/drugs/DB05032InvestigationalIt is a topically delivered small protein that acts as an anti-inflammatory agent.
Pelitinib
go.drugbank.com/drugs/DB05524InvestigationalPelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.
Halazepam
go.drugbank.com/drugs/DB00801ApprovedIllicitWithdrawnHalazepam is a benzodiazepine derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects. It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United S...
Frovatriptan
go.drugbank.com/drugs/DB00998ApprovedFrovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head.
Dicloxacillin
go.drugbank.com/drugs/DB00485ApprovedInvestigationalVet approvedOne of the penicillins which is resistant to penicillinase.
Lesinurad
go.drugbank.com/drugs/DB11560ApprovedWithdrawnMarketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target